1、 秦环龙,尹明明.肠道微生态和肠道营养[J].中华普通外科学文献(电子版),2015,(3):182-187. 秦环龙,尹明明.肠道微生态和肠道营养[J].中华普通外科学文献(电子版),2015,(3):182-187.
2、 谢莉,高微微,卜建玲,等.702例抗结核药物所致不良反应分析[J].中国防痨杂志,2008(4):275-278. 谢莉,高微微,卜建玲,等.702例抗结核药物所致不良反应分析[J].中国防痨杂志,2008(4):275-278.
3、 孙玉霞,赵善良,刘加洪,等.强化四周抗结核药物治疗对结核病患者肠道微生态影响分析[J].实用预防医学,2019,26(10):1177-1182. 孙玉霞,赵善良,刘加洪,等.强化四周抗结核药物治疗对结核病患者肠道微生态影响分析[J].实用预防医学,2019,26(10):1177-1182.
4、 NAMASIVAYAM S, MAIGA M, YUAN W,et al. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy[J]. Microbiome,2017,5(1):71. NAMASIVAYAM S, MAIGA M, YUAN W,et al. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy[J]. Microbiome,2017,5(1):71.
5、 LUO M,LIU Y,WU P F,et al. Alternation of gut microbiota in patients with pulmonary tuberculosis[J]. Front Physiol,2017(8):822. LUO M,LIU Y,WU P F,et al. Alternation of gut microbiota in patients with pulmonary tuberculosis[J]. Front Physiol,2017(8):822.
6、 WIPPERMAN M F, FITZGERALD D W, JUSTE M A J,et al. Antibiotic treatment for tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed[J].Sci Rep,2017,7(1):10767. WIPPERMAN M F, FITZGERALD D W, JUSTE M A J,et al. Antibiotic treatment for tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed[J].Sci Rep,2017,7(1):10767.
7、 WINGLEE K, ELOE-FADROSH E, GUPTA S,et al. Aerosol Mycobacterium tuberculosis infection causes rapid loss of diversity in gut microbiota[J].PloS One,2014,9(5):e97048. WINGLEE K, ELOE-FADROSH E, GUPTA S,et al. Aerosol Mycobacterium tuberculosis infection causes rapid loss of diversity in gut microbiota[J].PloS One,2014,9(5):e97048.
8、 DUBOURG G, LAGIER J C, ARMOUGOM F,et al. The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics[J].Eur J Clin Microbiol Infect Dis,2013,32(5):637–645. DUBOURG G, LAGIER J C, ARMOUGOM F,et al. The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics[J].Eur J Clin Microbiol Infect Dis,2013,32(5):637–645.
9、 HU Y F,FENG Y Q,WU J N,et al. The gut microbiome signatures discriminate healthy from pulmonary tuberculosis patients[J].Front cell infec microbiol,2019(9):90. HU Y F,FENG Y Q,WU J N,et al. The gut microbiome signatures discriminate healthy from pulmonary tuberculosis patients[J].Front cell infec microbiol,2019(9):90.
10、 BALCELLS M E, YOKOBORI N, HONG B Y,et al. The lung microbiome, vitamin D, and the tuberculous granuloma: A balance triangle[J].Microb Pathog,2019(131):158-163. BALCELLS M E, YOKOBORI N, HONG B Y,et al. The lung microbiome, vitamin D, and the tuberculous granuloma: A balance triangle[J].Microb Pathog,2019(131):158-163.
11、 NAIDOO C C, NYAWO G R, WU B G,et al. The microbiome and tuberculosis: state of the art, potential applications, and defining the clinical research agenda[J]. Lancet Respir Med,2019,7(10): 892-906. NAIDOO C C, NYAWO G R, WU B G,et al. The microbiome and tuberculosis: state of the art, potential applications, and defining the clinical research agenda[J]. Lancet Respir Med,2019,7(10): 892-906.
12、 PERRY S, de JONG B C, SOLNICK J V,et al. Infection with helicobacter pylori is associated with protection against tuberculosis[J]. PLoS One,2010,5(1):e8804. PERRY S, de JONG B C, SOLNICK J V,et al. Infection with helicobacter pylori is associated with protection against tuberculosis[J]. PLoS One,2010,5(1):e8804.
13、 HE Y,WEN Q,YAO F F,et al. Gut-lung axis: The microbial contributions and clinical implications[J].Crit Rev Microbiol,2017,43(1):81-95. HE Y,WEN Q,YAO F F,et al. Gut-lung axis: The microbial contributions and clinical implications[J].Crit Rev Microbiol,2017,43(1):81-95.
14、 GRICE E A,SEGRE J A.The human microbiome: our second genome[J]. Annu Rev Genomics Hum Genet, 2012, 13(1):151-170. GRICE E A,SEGRE J A.The human microbiome: our second genome[J]. Annu Rev Genomics Hum Genet, 2012, 13(1):151-170.
15、 丁瑞东. 利福平与利福喷汀治疗肺结核的临床疗效及不良反应对比研究[J]. 国际医药卫生导报, 2017,23(9):1407-1409. 丁瑞东. 利福平与利福喷汀治疗肺结核的临床疗效及不良反应对比研究[J]. 国际医药卫生导报, 2017,23(9):1407-1409.
16、 陈艳.利福喷汀和利福平治疗肺结核的临床疗效比较研究及安全性分析[J].临床合理用药杂志,2017,10(6):5-7. 陈艳.利福喷汀和利福平治疗肺结核的临床疗效比较研究及安全性分析[J].临床合理用药杂志,2017,10(6):5-7.
17、 张培元.肺结核诊断和治疗指南[J].中华结核和呼吸杂志,2001,24(2):70-74. 张培元.肺结核诊断和治疗指南[J].中华结核和呼吸杂志,2001,24(2):70-74.
18、 王浩然,姚娇,赵德明,等.肠道菌群改变与结核分枝杆菌感染相互作用的研究进展[J].微生物学通报,2021,48(4):1273-1280. 王浩然,姚娇,赵德明,等.肠道菌群改变与结核分枝杆菌感染相互作用的研究进展[J].微生物学通报,2021,48(4):1273-1280.
19、 ERIBO O A, du PLESSIS N, OZTURK M,et al. The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty?[J]. Cell Mol Life Sci,2020,77(3):1497-1509. ERIBO O A, du PLESSIS N, OZTURK M,et al. The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty?[J]. Cell Mol Life Sci,2020,77(3):1497-1509.
20、 KONTUREK P C, HAZIRI D, BRZOZOWSKI T, et al. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases[J]. J Physiol Pharmacol, 2015, 66(4):483-491. KONTUREK P C, HAZIRI D, BRZOZOWSKI T, et al. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases[J]. J Physiol Pharmacol, 2015, 66(4):483-491.
21、 谢锦慧,向延根,喻容,等.肠道菌群对机体抗结核免疫反应影响研究进展[J].标记免疫分析与临床,2021,28(8):1430-1434. 谢锦慧,向延根,喻容,等.肠道菌群对机体抗结核免疫反应影响研究进展[J].标记免疫分析与临床,2021,28(8):1430-1434.
22、 向毅,巫贵成.肠道微生态的基本概念[J].现代医药卫生,2019,35(1):5-7. 向毅,巫贵成.肠道微生态的基本概念[J].现代医药卫生,2019,35(1):5-7.
23、 CHAKAYA J, KHAN M, NTOUMI F,et al. Global Tuberculosis Report 2020 - Reflections on the global TB burden, treatment and prevention efforts[J]. Int J Infect Dis,2021,S1201-9712(21):193-194. CHAKAYA J, KHAN M, NTOUMI F,et al. Global Tuberculosis Report 2020 - Reflections on the global TB burden, treatment and prevention efforts[J]. Int J Infect Dis,2021,S1201-9712(21):193-194.
